# Generated by ReviewAid
Filename,Title,Author,Year,Confidence,Reason for Inclusion
1-s2.0-S0022510X21003166-main.pdf,Wearing-off symptoms during standard and extended natalizumab dosing intervals: Experiences from the COVID-19 pandemic,Gerd Haga Bringeland,2021,0.95,"The paper focuses on adults with multiple sclerosis (MS) receiving natalizumab, evaluating the effect of extended interval dosing (EID) compared to standard interval dosing (SID) on wearing-off symptoms. This aligns with the PICO criteria: population (adults), intervention (natalizumab, SID/EID), and outcomes (MS)."
